# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2019 Earnings Results

**Report date:** 2019-11-05 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2019

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 6.93%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.67 | N/A | +2.63% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed confidence in the company's performance and highlighted the strength of their product pipeline. They emphasized their commitment to innovation and growth.

**Key quotes:**

> We are pleased with our performance this quarter.

> Our pipeline remains strong and we are focused on future growth.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong earnings per share beat expectations, which contributed to a 6.93% increase in stock price following the report. The absence of revenue figures leaves some uncertainty, but management's confident tone suggests they are optimistic about future performance. Investors may view this earnings surprise positively as a sign of the company's ongoing strength.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2019_